- Home
- VMD vs AQST Comparison
VMD vs AQST Comparison
Compare VMD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | AQST |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.2M | 504.0M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | VMD | AQST |
|---|---|---|
| Price | $9.65 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 241.6K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $270,280,000.00 | $67,430,000.00 |
| Revenue This Year | $17.88 | $10.08 |
| Revenue Next Year | $14.98 | $49.60 |
| P/E Ratio | $160.83 | ★ N/A |
| Revenue Growth | ★ 20.52 | 0.77 |
| 52 Week Low | $5.93 | $2.38 |
| 52 Week High | $10.18 | $7.55 |
Technical Indicators
Market Signals| Indicator | VMD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 47.82 |
| Support Level | $9.22 | $4.02 |
| Resistance Level | $10.04 | $4.38 |
| Average True Range (ATR) | 0.45 | 0.22 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 90.94 | 14.90 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.